AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL 44310.; as amended from time to time.
PUBLIC HEALTH SERVICEAgreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Ninth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Ninth Amendment to the Transaction (this “Amendment”) is effective as of February 17, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”)
AMENDMENT TO EMPLOYMENT AGREEMENT & RESIGNATION FROM BOARD OF DIRECTORSEmployment Agreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Dr. Barry Ginsberg an individual (“the employee”) with an address of 3601 NW 24th Avenue, Boca Raton FL 33431; as amended from time to time.
Eleventh Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Eleventh Amendment to the Transaction (this “Amendment”) is effective as of April 5, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”)
PUBLIC HEALTH SERVICE AmendmentAgreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Agreement is based on the model Amendment Agreement adopted by the US Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Twelfth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Twelfth Amendment to the Transaction (this “Amendment”) is effective as of May 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”).
Thirteenth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Thirteenth Amendment to the Transaction (this “Amendment”) is effective as of July 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”).
PUBLIC HEALTH SERVICE AmendmentConfidential - • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
2nd AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL 44310.; as amended from time to time.
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and I Richard Garr an individual (“the employee”) with an address of 1024 Casuarina Rd. Delray Beach FL 44384, now 8803 Maxwell Drive Potomac, MD 20854.; as amended from time to time.
Eighth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Eighth Amendment to the Transaction (this “Amendment”) is effective as of January 31, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”)
Fifteenth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Fifteenth Amendment to the Transaction (this “Amendment”) is effective as of December 18, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”).
Sixteenth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Sixteenth Amendment to the Transaction (this “Amendment”) is effective as of January 29, 2024 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”).
Fourteenth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Fourteenth Amendment to the Transaction (this “Amendment”) is effective as of December 1, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”).
Tenth Amendment to Transaction DocumentsTransaction Documents • May 6th, 2024 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This Tenth Amendment to the Transaction (this “Amendment”) is effective as of March 16, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, as amended, entered between the Parties (the “Securities Purchase Agreement”)
